Results 81 to 90 of about 1,626,261 (197)
Long-acting amylin analogues for the management of obesity
PURPOSE OF REVIEW: To summarize recent developments of long-acting amylin analogues for the treatment of obesity and to outline their mode of action. RECENT FINDINGS: Amylin is a pancreatic hormone acting to control energy homeostasis and body weight ...
Mathiesen, David S. +5 more
core +1 more source
Trends in Anti‐Hyperglycemic Medicines Among US Adults With Diabetes and a History of Stroke
In MEPS 2017'2023, 2,241 person‐years represented approximately 3.05 million U.S. adults with diabetes and a history of stroke annually. Survey‐weighted use of GLP‐1RAs or SGLT2 inhibitors increased from 8.7% to 33.8% (OR per year, 1.36; P < 0.001). Stroke‐history associations with insulin and metformin use attenuated after clinical adjustment and did ...
Yaojie Cai, Yu‐Jun Xiong, Tian Lv
wiley +1 more source
Amylin, CGRP and the AMY1 receptor: Localisation in the trigeminal ganglia and receptor regulation
Calcitonin gene-related peptide (CGRP) is a neuromodulatory peptide that is highly expressed in the nervous system. It is involved in several physiological and pathophysiological processes, including pain and migraine.
Rees, Tayla Anne
core
Bibliometric analysis of 3736 publications (2004–2025) reveals rapid growth in GLP‐1–based T2DM research. The US leads, with Novo Nordisk and Eli Lilly as top contributors. Thematic shifts from glycemic control toward cardiovascular‐kidney‐metabolic outcomes and real‐world evidence, driven by landmark trials like LEADER and REWIND.
Yanbing Wang +6 more
wiley +1 more source
Amylin: Pharmacology, Physiology, and Clinical Potential [PDF]
Amylin is a pancreatic β-cell hormone that produces effects in several different organ systems. Here, we review the literature in rodents and in humans on amylin research since its discovery as a hormone about 25 years ago.
Roth, Jonathan D +9 more
core +1 more source
Calcitonin, CGRP, adrenomedullin, and amylin require both CRLR (calcitonin-gene receptor like receptor) and receptor activity modifying proteins (RAMP1, RAMP2, and RAMP3) in different combinations for expression of selective, functional receptors[1].
Z. Razzaque +6 more
doaj +1 more source
ABSTRACT Objective High‐fat diet represses Ceacam1 transcription via a PPARα‐mediated mechanism to cause insulin resistance before inflammation develops. The current study investigated whether mutating PPRE‐RXRα in Ceacam1 promoter prevents diet‐induced metabolic abnormalities and hepatic fibrosis in male C57BL6/J mice.
Raziyeh Abdolahipour +9 more
wiley +1 more source
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. [PDF]
Obesity affects over 2 billion adults globally, with projections indicating that nearly two-thirds of adults will be affected by 2050. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity treatment, achieving weight loss ...
Lempesis IG, Dalamaga M.
europepmc +2 more sources
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3Research in context
Summary: Background: Amylin (AmyR) and calcitonin (CTR) receptor co-agonists are currently in Phase II/III clinical trials for obesity treatment. Amylin binds to a heterodimeric receptor composed of CTR and the receptor activity modifying proteins 1, 2 ...
Alexandra Oliveira Carvas +11 more
doaj +1 more source
The gut-brain axis and alcohol-mediated behaviours: the amylin story [PDF]
Alcohol use disorder (AUD) is a complex neuropsychiatric disorder with high rates of mortality and morbidity. The currently available pharmacotherapies show varied efficacy, leading to the investigation of new neurochemical targets for alcohol ...
Kalafateli, Aimilia Lydia +6 more
core +1 more source

